XTL Biopharmaceuticals Pivoting down. XTLBOr so we believe. Not really basing this one on Elliott Waves - none have yet occurred in the consolidation phase yet. And that is fine. In our experience, provided we are correct in the assertion that the impulse is truly over, we can infer that there is a high chance for a retrace to a level. Inn
−0.11 USD
−1.03 M USD
451.00 K USD
8.60 M
About XTL Biopharmaceuticals Ltd.
Sector
Industry
CEO
Noam Band
Website
Headquarters
Ramat Gan
Founded
1993
ISIN
US98386D3070
FIGI
BBG000F1JVP4
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.